BERKELEY, Calif., March 11 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: NILT), today announced that it will release fourth quarter and full year financial results for 2007 after the market closes on Thursday, March 13, 2008. Nile management will host a conference call and live webcast to discuss these financial results and provide an update on each of its development programs at 4:30 p.m. ET, 1:30 p.m. PT that afternoon.
Interested investors may participate in the conference call by dialing 877-548-7906 (domestic) or +1-719-325-4883 (international). Participants may also access both the live and archived webcast of the conference call from the homepage and the investor relations section of Nile's website at http://www.nilethera.com. The webcast will remain available on the company's website until the next quarterly conference call.
About Nile Therapeutics
Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company
that develops innovative products for the treatment of cardiovascular
disease and other areas of unmet medical need. Nile is initially focusing
its efforts on developing its lead compound, CD-NP, a novel chimeric
peptide in Phase I studies for the treatment of heart failure, and 2NTX-99,
a small molecule, pre-clinical, anti-atherothrombotic agent with nitric
oxide donating properties. A key component of the company's strategy is to
acquire the global rights to additional compounds to expand its portfolio.
More information on Nile can be found at http://www.nilethera.com.
Chief Financial Officer
Nile Therapeutics, Inc.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 19
|SOURCE Nile Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved